Scarica l'app Stockscreener
10.69
3.19%
0.33
Dopo l'orario di chiusura:
10.48
-0.21
-1.96%
Precedente Chiudi:
$10.36
Aprire:
$10.19
Volume 24 ore:
1.12M
Relative Volume:
0.88
Capitalizzazione di mercato:
$935.35M
Reddito:
-
Utile/perdita netta:
$-185.15M
Rapporto P/E:
-5.2782
EPS:
-2.0253
Flusso di cassa netto:
$-148.72M
1 W Prestazione:
-0.37%
1M Prestazione:
-10.47%
6M Prestazione:
-32.17%
1 anno Prestazione:
+36.88%
Intervallo 1D:
$10.11
$10.98
Intervallo di 1 settimana:
$10.11
$11.18
Portata 52W:
$6.65
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Nome
Olema Pharmaceuticals Inc
Settore
Industria
Telefono
(415) 651-3316
Indirizzo
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
10.69 | 906.48M | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-19 | Ripresa | Jefferies | Buy |
| 2026-02-11 | Iniziato | Stifel | Buy |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-12 | Reiterato | Citigroup | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2024-01-30 | Iniziato | Citigroup | Buy |
| 2023-07-21 | Iniziato | Oppenheimer | Outperform |
| 2023-05-05 | Iniziato | CapitalOne | Overweight |
| 2023-02-22 | Iniziato | Credit Suisse | Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Iniziato | H.C. Wainwright | Neutral |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2020-12-14 | Iniziato | Canaccord Genuity | Buy |
| 2020-12-14 | Iniziato | Cowen | Outperform |
| 2020-12-14 | Iniziato | JP Morgan | Overweight |
| 2020-12-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Olema Pharmaceuticals Inc Borsa (OLMA) Ultime notizie
Olema Oncology at citigroup summit: palazestrant data, delays - Investing.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 3.5%Should You Buy? - marketbeat.com
Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1'27 (NASDAQ:OLMA) - Seeking Alpha
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA - marketbeat.com
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - marketbeat.com
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA - marketbeat.com
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne - Quiver Quantitative
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036 - Stock Titan
A new finance chief gets options on 650,000 Olema shares - Stock Titan
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
BlackRock Inc. Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - marketbeat.com
Olema Pharmaceuticals Inc. (OLMA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Olema Pharmaceuticals Inc. (OLMA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Jupiter Topco LLC Takes $88.80 Million Position in Olema Pharmaceuticals, Inc. $OLMA - marketbeat.com
Bank of America Corp DE Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:OLMA) - MarketBeat
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Olema Oncology appoints Jason O’Byrne as CFO - The Pharma Letter
OLMA Maintained by JP Morgan -- Price Target Lowered to $46.00 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals, Inc. Announces Appointment of Jason O?Byrne to Chief Financial Officer, Effective August 11, 2026 - marketscreener.com
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46 - moomoo.com
Olema Pharmaceuticals Names Jason O'Byrne as New CFO with Comprehensive Compensation Package - Kalkine Media
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
HC Wainwright Brokers Decrease Earnings Estimates for OLMA - MarketBeat
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - The Manila Times
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech - Stock Titan
Olema Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harmon Cyrus - Moomoo
Olema stock falls 12.9% as Q2 loss widens to $63.2M on R&D spend - scanx.trade
OLMA Maintains Rating by Citigroup -- Price Target Lowered to $5 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup - MarketBeat
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 - TradingView
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings - MarketBeat
Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39.9, Implies 234% Upside - TradingView
OLMA Maintains Buy Rating -- Price Target Lowered to $36.00 by H - GuruFocus
H.C. Wainwright lowers Olema Pharmaceuticals price target to $36 By Investing.com - Investing.com Canada
Olema Pharmaceuticals Q2 Loss Widens - marketscreener.com
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss - marketscreener.com
Olema Oncology (OLMA) Advances Phase 3 Trial Enrollment Amid Mixed Market Signals - GuruFocus
Olema Pharmaceuticals falls 6% on second quarter EPS miss By Investing.com - Investing.com Canada
Olema Pharmaceuticals falls 6% on second quarter EPS miss - Investing.com
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Olema Pharmaceuticals (OLMA) widens net loss but ends Q2 2026 with $461M in cash - Stock Titan
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results - Yahoo Finance
Olema Pharmaceuticals earnings up next ahead of key trial data By Investing.com - Investing.com Canada
Olema Pharmaceuticals Inc Azioni (OLMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):